Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

NCT00998192 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT00998192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00998192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Lead sponsor
Oncolytics Biotech
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
August 31, 2015
Enrollment
32 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or recurrent squamous cell carcinoma of the lung